<DOC>
	<DOCNO>NCT00003152</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Radiation therapy use high-energy x-rays damage cancer cell . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug radiation therapy kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy follow interferon alfa alone combination chemotherapy plus radiation therapy peripheral stem cell transplantation treat patient previously untreated stage III stage IV follicular non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy Plus Interferon Alfa Alone With Radiation Therapy Peripheral Stem Cell Transplantation Treating Patients With Stage III Stage IV Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare progression free overall survival , toxicity , mortality marrow ablative chemo/radiotherapy addition peripheral blood stem cell transplantation interferon alfa maintenance therapy versus interferon alfa maintenance therapy alone patient follicular non-Hodgkin 's lymphoma . OUTLINE : This randomize study . All patient receive 8 course cyclophosphamide/vincristine/prednisone ( CVP ) chemotherapy . Cyclophosphamide vincristine IV give day 1 , along oral prednisone day 1-5 . Courses repeat every 3 week . Patients randomize receive one two treatment 4 week completion CVP chemotherapy partial complete response achieve less 15 % monoclonal B-lymphocytes bone marrow . Patients randomized arm I receive interferon alfa subcutaneously 3 time per week maximum 3 year . Patients randomize arm II receive cyclophosphamide IV follow subcutaneous filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) . Leukapheresis begin leukocyte , platelet , CD34+ level recover last 3-4 hour 2-3 consecutive day . If insufficient number stem cell collect peripheral blood , bone marrow harvest perform . After stem cell collection , condition regimen consist cyclophosphamide IV day -4 -3 total body irradiation day -1 administer . Stem cell infuse day 0 . If granulocyte platelet count recover within 8 week , patient receive interferon alfa maintenance therapy arm I . Patients follow every 4 month death . PROJECTED ACCRUAL : A total 469 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously untreated follicular stage III IV nonHodgkin 's lymphoma At least one measurable mass PATIENT CHARACTERISTICS : Age : 18 65 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Alkaline phosphatase bilirubin le 2.5 time upper limit normal ( ULN ) ( unless clearly relate NHL ) Renal : Creatinine BUN less 2.5 time ULN ( unless clearly relate NHL ) Cardiovascular : No severe cardiac disease ( e.g . severe heart failure require treatment cardiac ejection fraction le 45 % ) Neurologic : No neurologic disease Pulmonary : No pulmonary disease Other : Not pregnant No prior malignancy except nonmelanoma skin cancer carcinoma situ cervix Not HIV positive No psychiatric metabolic disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent immunotherapeutic drug , chemotherapy , radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>